Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences Inc (NQ: ENSC )

0.4618 -0.0063 (-1.35%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 48,357
Open 0.4611
Bid (Size) 0.4612 (1)
Ask (Size) 0.4700 (31)
Prev. Close 0.4681
Today's Range 0.4611 - 0.4780
52wk Range 0.4390 - 2.210
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
Via ACCESSWIRE
Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
Via ACCESSWIRE

Performance

YTD
-58.40%
-58.40%
1 Month
-12.39%
-12.39%
3 Month
-26.68%
-26.68%
6 Month
-59.84%
-59.84%
1 Year
-77.80%
-77.80%

More News

Read More
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
Via ACCESSWIRE
ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Via ACCESSWIRE
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Ensysce Biosciences Regains Compliance with Nasdaq
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
Via ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
Via ACCESSWIRE
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Via ACCESSWIRE
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Via ACCESSWIRE
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Via ACCESSWIRE
FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today
Via InvestorPlace
ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Via ACCESSWIRE
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
Via ACCESSWIRE
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
Via ACCESSWIRE
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.